1	PRINCETON	princeton	NNP	p2=NN	0	root	_
2	,	,	,	_	1	punct	_
3	N.J.	n.j.	NNP	_	1	conj	_
4	&	&	CC	_	3	cc	_
5	NORTH	north	NNP	_	6	nn	_
6	CHICAGO	chicago	NNP	_	3	conj	_
7	,	,	,	_	6	punct	_
8	Ill	ill	NNP	_	6	appos	_
9	.	.	.	_	1	punct	_

1	--	--	:	p2=.	4	punct	_
2	(	(	-LRB-	_	4	punct	_
3	BUSINESS	business	NNP	p2=NN	4	nn	_
4	WIRE	wire	NNP	_	21	nsubj	21:A0=PAG
5	)	)	-RRB-	_	4	punct	_
6	--	--	:	_	4	punct	_
7	Bristol	bristol	NNP	_	9	hmod	_
8	-	-	HYPH	_	9	hyph	_
9	Myers	myers	NNP	_	11	nn	_
10	Squibb	squibb	NNP	_	11	nn	_
11	Company	company	NNP	_	4	dep	_
12	(	(	-LRB-	_	11	punct	_
13	NYSE:BMY	#url#	ADD	_	11	appos	_
14	)	)	-RRB-	_	11	punct	_
15	and	and	CC	_	4	cc	_
16	AbbVie	abbvie	NNP	_	4	conj	_
17	(	(	-LRB-	_	16	punct	_
18	NYSE:ABBV	#url#	ADD	_	16	appos	_
19	)	)	-RRB-	_	16	punct	_
20	today	today	NN	_	21	npadvmod	21:AM-TMP
21	announced	announce	VBD	pb=announce.01	0	root	_
22	that	that	IN	_	33	complm	_
23	the	the	DT	_	28	det	_
24	U.S.	u.s.	NNP	_	28	nn	_
25	Food	food	NNP	_	28	nn	_
26	and	and	CC	_	25	cc	_
27	Drug	drug	NNP	_	25	conj	_
28	Administration	administration	NNP	_	33	nsubj	33:A0=PAG
29	(	(	-LRB-	_	30	punct	_
30	FDA	fda	NNP	_	28	appos	_
31	)	)	-RRB-	_	30	punct	_
32	has	have	VBZ	_	33	aux	_
33	granted	grant	VBN	pb=grant.01	21	ccomp	21:A1=PPT
34	elotuzumab	elotuzumab	JJR	p2=NNP	33	dobj	_
35	,	,	,	_	33	punct	_
36	an	an	DT	_	40	det	_
37	investigational	investigational	JJ	p2=NN	40	amod	_
38	humanized	humanize	VBN	p2=JJ|pb=humanize.01	40	amod	_
39	monoclonal	monoclonal	JJ	p2=NN	40	amod	_
40	antibody	antibody	NN	_	33	dobj	33:A1;38:A1=PPT
41	,	,	,	_	40	punct	_
42	Breakthrough	breakthrough	NNP	_	44	nn	_
43	Therapy	therapy	NNP	_	44	nn	_
44	Designation	designation	NNP	p2=NN	40	appos	_
45	for	for	IN	_	33	prep	_
46	use	use	NN	_	45	pobj	_
47	in	in	IN	_	46	prep	_
48	combination	combination	NN	_	47	pobj	_
49	with	with	IN	_	48	prep	_
50	lenalidomide	lenalidomide	NN	p2=JJ	49	pobj	_
51	and	and	CC	_	50	cc	_
52	dexamethasone	dexamethasone	NN	p2=VBN	50	conj	_
53	for	for	IN	_	50	prep	_
54	the	the	DT	_	55	det	_
55	treatment	treatment	NN	_	53	pobj	_
56	of	of	IN	_	55	prep	_
57	multiple	multiple	JJ	_	58	amod	_
58	myeloma	myeloma	NN	p2=NNS	56	pobj	_
59	in	in	IN	_	55	prep	_
60	patients	patient	NNS	_	59	pobj	63:A0=PAG
61	who	who	WP	_	63	nsubj	63:R-A0
62	have	have	VBP	_	63	aux	_
63	received	receive	VBN	pb=receive.01	60	rcmod	_
64	one	#crd#	CD	_	68	num	_
65	or	or	CC	_	64	cc	_
66	more	more	JJR	p2=RBR	64	conj	_
67	prior	prior	JJ	p2=RB	68	amod	_
68	therapies	therapy	NNS	_	63	dobj	63:A1=PPT
69	.	.	.	_	21	punct	_

1	The	the	DT	_	2	det	_
2	designation	designation	NN	_	4	nsubjpass	4:A1=PPT
3	is	be	VBZ	_	4	auxpass	_
4	based	base	VBN	pb=base.02	0	root	_
5	on	on	IN	_	4	prep	4:A2=DIR
6	findings	finding	NNS	_	5	pobj	_
7	from	from	IN	_	6	prep	_
8	a	a	DT	_	10	det	_
9	randomized	randomize	VBN	p2=JJ|pb=randomize.01	10	amod	_
10	Phase	phase	NN	p2=NNP	7	pobj	9:A1=PPT
11	2	0	CD	_	10	num	_
12	,	,	,	_	16	punct	_
13	open	open	JJ	_	15	hmod	_
14	-	-	HYPH	_	15	hyph	_
15	label	label	NN	_	16	nn	_
16	study	study	NN	_	10	appos	18:A0=PAG
17	that	that	WDT	_	18	nsubj	18:R-A0
18	evaluated	evaluate	VBD	pb=evaluate.01	16	rcmod	_
19	two	#crd#	CD	_	21	num	_
20	dose	dose	NN	_	21	nn	_
21	levels	level	NNS	_	18	dobj	18:A1=PPT
22	of	of	IN	_	21	prep	_
23	elotuzumab	elotuzumab	NN	p2=VBG	22	pobj	_
24	in	in	IN	_	21	prep	_
25	combination	combination	NN	_	24	pobj	_
26	with	with	IN	_	21	prep	_
27	lenalidomide	lenalidomide	JJ	p2=NN	53	amod	_
28	and	and	CC	_	27	cc	_
29	low	low	JJ	_	31	hmod	_
30	-	-	HYPH	_	31	hyph	_
31	dose	dose	NN	_	32	nn	_
32	dexamethasone	dexamethasone	NN	_	26	pobj	_
33	in	in	IN	_	32	prep	_
34	previously	previously	RB	_	36	hmod	_
35	-	-	HYPH	_	36	hyph	_
36	treated	treat	VBN	_	37	amod	_
37	patients	patient	NNS	_	33	pobj	_
38	,	,	,	_	37	punct	_
39	including	include	VBG	_	37	prep	_
40	the	the	DT	_	45	det	_
41	10	0	CD	_	44	num	_
42	mg	mg	NN	p2=NNS	44	nn	_
43	/	/	SYM	p2=WRB	44	punct	_
44	kg	kg	NNS	p2=NN	45	nn	_
45	dose	dose	NN	p2=VBP	39	pobj	49:A1=PPT
46	that	that	WDT	_	49	nsubjpass	49:R-A1
47	is	be	VBZ	_	49	aux	_
48	being	be	VBG	_	49	auxpass	_
49	studied	study	VBN	pb=study.01	45	rcmod	_
50	in	in	IN	_	49	prep	49:AM-LOC
51	Phase	phase	NNP	p2=NN	53	nn	_
52	3	0	CD	_	51	num	_
53	trials	trial	NNS	_	50	pobj	_
54	.	.	.	_	4	punct	_

1	Data	data	NNP	p2=NN	10	nsubjpass	10:A1=PPT
2	from	from	IN	_	1	prep	_
3	the	the	DT	_	6	det	_
4	Phase	phase	NNP	p2=NN	6	nn	_
5	2	0	CD	_	4	num	_
6	trial	trial	NN	_	2	pobj	_
7	were	be	VBD	_	10	auxpass	_
8	most	most	RBS	_	9	advmod	_
9	recently	recently	RB	_	10	advmod	10:AM-TMP
10	presented	present	VBN	pb=present.01	0	root	_
11	at	at	IN	_	10	prep	10:AM-LOC
12	the	the	DT	_	15	det	_
13	18th	#ord#	JJ	p2=NNP	15	amod	_
14	Annual	annual	NNP	_	15	nn	_
15	Congress	congress	NNP	_	11	pobj	_
16	of	of	IN	_	15	prep	_
17	the	the	DT	_	20	det	_
18	European	european	NNP	p2=JJ	20	nn	_
19	Hematology	hematology	NNP	_	20	nn	_
20	Association	association	NNP	_	16	pobj	_
21	(	(	-LRB-	_	22	punct	_
22	EHA	eha	NNP	_	20	appos	_
23	)	)	-RRB-	_	22	punct	_
24	in	in	IN	_	10	prep	10:AM-TMP
25	2013	0	CD	p2=NNP	24	pobj	_
26	(	(	-LRB-	_	27	punct	_
27	click	click	VB	p2=NN|pb=click.01	10	parataxis	_
28	here	here	RB	_	27	advmod	27:AM-LOC
29	to	to	TO	p2=IN	30	aux	_
30	view	view	VB	pb=view.01	27	advcl	27:AM-PRP
31	press	press	NN	_	32	nn	_
32	release	release	NN	p2=VB	30	dobj	30:A1=PAG
33	)	)	-RRB-	_	27	punct	_
34	.	.	.	_	10	punct	_

1	According	accord	VBG	_	10	prep	10:AM-ADV
2	to	to	IN	_	1	prep	_
3	the	the	DT	_	4	det	_
4	FDA	fda	NNP	_	2	pobj	_
5	,	,	,	_	10	punct	_
6	Breakthrough	breakthrough	NNP	_	8	nn	_
7	Therapy	therapy	NNP	_	8	nn	_
8	Designation	designation	NNP	p2=NN	10	nsubjpass	12:A0=PAG;10:A2=VSP
9	is	be	VBZ	_	10	auxpass	_
10	intended	intend	VBN	pb=intend.01	0	root	_
11	to	to	TO	_	12	aux	_
12	expedite	expedite	VB	pb=expedite.01	10	xcomp	10:A1=PPT
13	the	the	DT	_	14	det	_
14	development	development	NN	_	12	dobj	12:A1=PPT
15	and	and	CC	_	14	cc	_
16	review	review	NN	_	14	conj	_
17	of	of	IN	_	14	prep	_
18	drugs	drug	NNS	_	17	pobj	_
19	for	for	IN	_	14	prep	_
20	serious	serious	JJ	_	25	amod	_
21	or	or	CC	_	20	cc	_
22	life	life	NN	_	24	hmod	_
23	-	-	HYPH	_	24	hyph	_
24	threatening	threaten	VBG	_	20	conj	_
25	conditions	condition	NNS	_	19	pobj	_
26	.	.	.	_	10	punct	_

1	The	the	DT	_	2	det	_
2	criteria	criterion	NNS	_	7	nsubj	7:A0=PAG
3	for	for	IN	_	2	prep	_
4	Breakthrough	breakthrough	NNP	_	6	nn	_
5	Therapy	therapy	NNP	_	6	nn	_
6	Designation	designation	NNP	p2=NN	3	pobj	_
7	require	require	VBP	p2=VB|pb=require.01	0	root	_
8	preliminary	preliminary	JJ	_	10	amod	_
9	clinical	clinical	JJ	_	10	amod	_
10	evidence	evidence	NN	_	7	dobj	12:A0;7:A1=PPT
11	that	that	WDT	p2=IN	12	nsubj	12:R-A0
12	demonstrates	demonstrate	VBZ	pb=demonstrate.01	10	rcmod	_
13	the	the	DT	_	14	det	_
14	drug	drug	NN	_	16	nsubj	16:A0=PAG
15	may	may	MD	_	16	aux	16:AM-MOD
16	have	have	VB	pb=have.03	12	ccomp	12:A1=PPT
17	substantial	substantial	JJ	_	18	amod	_
18	improvement	improvement	NN	_	16	dobj	16:A1=PPT
19	on	on	IN	_	16	prep	16:AM-TMP
20	at	at	RB	p2=IN	21	advmod	_
21	least	least	RBS	p2=JJS	22	advmod	_
22	one	#crd#	CD	_	25	num	_
23	clinically	clinically	RB	p2=NN	24	advmod	_
24	significant	significant	JJ	_	25	amod	_
25	endpoint	endpoint	NN	p2=RB	19	pobj	_
26	over	over	IN	_	25	prep	_
27	available	available	JJ	_	28	amod	_
28	therapy	therapy	NN	_	26	pobj	_
29	.	.	.	_	7	punct	_

1	Elotuzumab	elotuzumab	NNP	p2=NN	2	nsubj	2:A1=PPT
2	is	be	VBZ	pb=be.01	24	ccomp	_
3	a	a	DT	_	7	det	_
4	humanized	humanize	VBN	p2=JJ|pb=humanize.01	7	amod	_
5	IgG1	igg1	NNP	p2=CD	7	nn	_
6	monoclonal	monoclonal	JJ	p2=NN	7	amod	_
7	antibody	antibody	NN	_	2	attr	4:A1=PPT;8:A1=PPT;2:A2=PRD
8	targeted	target	VBN	p2=VBD|pb=target.01	7	partmod	_
9	against	against	IN	_	8	prep	8:A2=MNR
10	Signaling	signaling	NNP	p2=VBG	13	nn	_
11	Lymphocyte	lymphocyte	NNP	_	13	nn	_
12	Activation	activation	NNP	_	13	nn	_
13	Molecule	molecule	NNP	_	9	pobj	_
14	(	(	-LRB-	_	18	punct	_
15	SLAMF7	slamf7	NNP	_	13	appos	_
16	,	,	,	_	18	punct	_
17	also	also	RB	_	18	advmod	18:AM-ADV
18	called	call	VBN	p2=VBD|pb=call.01	13	parataxis	_
19	CS1	cs1	NNP	p2=NN	18	oprd	18:A2=PRD
20	)	)	-RRB-	_	18	punct	_
21	,	,	,	_	24	punct	_
22	a	a	DT	_	23	det	_
23	glycoprotein	glycoprotein	NN	p2=NNP	24	nsubj	24:A0=PAG
24	expressed	express	VBD	p2=VBN|pb=express.01	0	root	_
25	on	on	IN	_	24	prep	24:AM-MNR
26	myeloma	myeloma	NN	p2=NNP	25	pobj	_
27	and	and	CC	_	26	cc	_
28	Natural	natural	NNP	p2=JJ	29	nn	_
29	Killer	killer	NNP	_	30	nn	_
30	cells	cell	NNS	_	26	conj	_
31	but	but	CC	_	24	cc	_
32	not	not	RB	_	33	neg	_
33	detectable	detectable	JJ	_	24	conj	_
34	in	in	IN	_	33	prep	_
35	normal	normal	JJ	_	36	amod	_
36	tissue	tissue	NN	_	34	pobj	_
37	.	.	.	_	24	punct	_

1	The	the	DT	_	2	det	_
2	company	company	NN	_	4	nsubj	4:A0
3	is	be	VBZ	_	4	aux	_
4	investigating	investigate	VBG	pb=investigate.01	0	root	_
5	whether	whether	IN	p2=RB	20	complm	_
6	through	through	IN	_	20	prep	20:AM-MNR
7	both	both	DT	p2=CC	9	preconj	_
8	direct	direct	JJ	_	9	amod	_
9	activation	activation	NN	_	6	pobj	_
10	and	and	CC	_	9	cc	_
11	engagement	engagement	NN	_	9	conj	_
12	of	of	IN	_	11	prep	_
13	Natural	natural	NNP	p2=JJ	14	nn	_
14	Killer	killer	NNP	_	15	nn	_
15	cells	cell	NNS	_	12	pobj	_
16	,	,	,	_	20	punct	_
17	elotuzumab	elotuzumab	NN	p2=FW	20	nsubj	20:A0=PAG;22:A0=PAG
18	may	may	MD	_	20	aux	20:AM-MOD;22:AM-MOD
19	selectively	selectively	RB	_	20	advmod	20:AM-MNR
20	target	target	VB	pb=target.01	4	ccomp	4:A1
21	and	and	CC	_	20	cc	_
22	kill	kill	VB	p2=VBP|pb=kill.01	20	conj	_
23	SLAMF7	slamf7	NNP	p2=NNS	22	dobj	22:A1=PPT
24	expressing	express	VBG	pb=express.01	22	advcl	22:AM-ADV
25	myeloma	myeloma	NN	_	26	nn	_
26	cells	cell	NNS	_	24	dobj	24:A1=PPT
27	.	.	.	_	4	punct	_

1	Elotuzumab	elotuzumab	NNP	p2=NN	4	nsubjpass	4:A1=PPT;22:A1=PPT
2	is	be	VBZ	_	4	aux	_
3	being	be	VBG	_	4	auxpass	_
4	studied	study	VBN	pb=study.01	0	root	_
5	as	as	IN	_	4	prep	4:AM-MNR
6	a	a	DT	_	7	det	_
7	monotherapy	monotherapy	NN	_	5	pobj	_
8	in	in	IN	_	7	prep	_
9	smoldering	smolder	VBG	pb=smolder.01	8	pcomp	_
10	myeloma	myeloma	NN	p2=NNS	9	dobj	_
11	and	and	CC	_	8	cc	_
12	in	in	IN	_	8	conj	_
13	combination	combination	NN	_	12	pobj	_
14	with	with	IN	_	13	prep	_
15	other	other	JJ	_	16	amod	_
16	therapies	therapy	NNS	_	14	pobj	_
17	in	in	IN	_	16	prep	_
18	first	#ord#	JJ	_	20	hmod	_
19	-	-	HYPH	_	20	hyph	_
20	line	line	NN	_	17	pobj	_
21	and	and	CC	_	4	cc	_
22	relapsed	relapse	VBD	p2=NN|pb=relapse.01	4	conj	_
23	or	or	CC	_	22	cc	_
24	refractory	refractory	JJ	p2=VB	26	amod	_
25	multiple	multiple	JJ	p2=NN	26	amod	_
26	myeloma	myeloma	NN	_	22	conj	_
27	.	.	.	_	4	punct	_

1	A	a	DT	_	4	det	_
2	clinical	clinical	JJ	_	4	amod	_
3	development	development	NN	_	4	nn	_
4	program	program	NN	_	8	nsubj	8:A1=PPT
5	for	for	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	agent	agent	NN	_	5	pobj	_
8	is	be	VBZ	pb=be.01	0	root	_
9	underway	underway	JJ	_	8	acomp	8:A2=PRD
10	,	,	,	_	8	punct	_
11	including	include	VBG	_	8	prep	_
12	Phase	phase	NN	p2=NNP	14	nn	_
13	3	0	CD	_	14	num	_
14	trials	trial	NNS	_	11	pobj	_
15	in	in	IN	_	14	prep	_
16	first	#ord#	JJ	_	18	hmod	_
17	-	-	HYPH	_	18	hyph	_
18	line	line	NN	_	20	nn	_
19	multiple	multiple	JJ	p2=NN	20	amod	_
20	myeloma	myeloma	NN	p2=FW	15	pobj	_
21	(	(	-LRB-	_	20	punct	_
22	ELOQUENT	eloquent	NNP	p2=FW	24	hmod	_
23	-	-	HYPH	p2=SYM	24	hyph	_
24	1	0	CD	p2=NNP	20	appos	_
25	)	)	-RRB-	_	20	punct	_
26	and	and	CC	_	14	cc	_
27	relapsed	relapse	VBN	p2=JJ|pb=relapse.01	14	conj	_
28	or	or	CC	_	14	cc	_
29	refractory	refractory	JJ	p2=VB	31	amod	_
30	multiple	multiple	JJ	p2=NN	31	amod	_
31	myeloma	myeloma	NN	_	14	conj	_
32	(	(	-LRB-	_	35	punct	_
33	ELOQUENT	eloquent	NNP	p2=FW	35	hmod	_
34	-	-	HYPH	p2=:	35	hyph	_
35	2	2	NNP	p2=CD	31	appos	_
36	)	)	-RRB-	_	35	punct	_
37	.	.	.	_	8	punct	_

1	Elotuzumab	elotuzumab	NNP	p2=NN	5	nsubjpass	5:A1
2	is	be	VBZ	_	5	aux	_
3	also	also	RB	_	5	advmod	5:AM-ADV
4	being	be	VBG	_	5	auxpass	_
5	investigated	investigate	VBN	pb=investigate.01	0	root	_
6	in	in	IN	_	5	prep	5:AM-MNR
7	a	a	DT	_	9	det	_
8	randomized	randomize	VBN	p2=JJ|pb=randomize.01	9	amod	_
9	Phase	phase	NN	p2=NNP	6	pobj	8:A1=PPT
10	2	0	CD	_	11	num	_
11	study	study	NN	_	9	appos	_
12	of	of	IN	_	11	prep	_
13	bortezomib	bortezomib	NN	p2=NNP	12	pobj	_
14	and	and	CC	_	13	cc	_
15	dexamethasone	dexamethasone	NN	p2=VBP	13	conj	_
16	in	in	IN	_	15	prep	_
17	relapsed	relapsed	JJ	p2=NN	21	amod	_
18	or	or	CC	_	17	cc	_
19	refractory	refractory	JJ	p2=NN	17	conj	_
20	multiple	multiple	JJ	p2=NN	21	amod	_
21	myeloma	myeloma	NN	_	16	pobj	_
22	.	.	.	_	5	punct	_

1	Elotuzumab	elotuzumab	NNP	p2=NN	4	nsubjpass	4:A1
2	is	be	VBZ	_	4	aux	_
3	being	be	VBG	_	4	auxpass	_
4	co-developed	co-develop	VBN	p2=JJ|pb=co-develop.01	0	root	_
5	with	with	IN	_	4	prep	4:A2
6	AbbVie	abbvie	NNP	_	5	pobj	_
7	,	,	,	_	4	punct	_
8	with	with	IN	_	4	prep	4:AM-MNR
9	Bristol	bristol	NNP	_	11	hmod	_
10	-	-	HYPH	_	11	hyph	_
11	Myers	myers	NNP	_	12	nn	_
12	Squibb	squibb	NNP	_	13	nsubj	13:A0=PAG
13	leading	lead	VBG	pb=lead.01	8	pcomp	_
14	the	the	DT	_	15	det	_
15	commercialization	commercialization	NN	_	13	dobj	13:A1=PPT
16	of	of	IN	_	15	prep	_
17	the	the	DT	_	18	det	_
18	agent	agent	NN	_	16	pobj	_
19	.	.	.	_	4	punct	_

1	Multiple	multiple	NNP	p2=JJ	2	nn	_
2	myeloma	myeloma	NN	p2=NNP	3	nsubj	3:A1=PPT
3	is	be	VBZ	pb=be.01	0	root	_
4	a	a	DT	_	7	det	_
5	progressive	progressive	JJ	_	7	amod	_
6	hematologic	hematologic	JJ	p2=NN	7	amod	_
7	cancer	cancer	NN	_	3	attr	9:A1=PPT;3:A2=PRD
8	that	that	WDT	p2=IN	9	nsubj	9:R-A1
9	originates	originate	VBZ	p2=VBP|pb=originate.01	7	rcmod	_
10	in	in	IN	_	9	prep	9:AM-LOC
11	the	the	DT	_	13	det	_
12	bone	bone	NN	_	13	nn	_
13	marrow	marrow	NN	_	10	pobj	_
14	.	.	.	_	3	punct	_

1	It	it	PRP	_	2	nsubj	2:A1=PPT;10:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	the	the	DT	_	8	det	_
4	second	#ord#	JJ	_	8	amod	_
5	most	most	RBS	p2=JJS	6	advmod	_
6	common	common	JJ	_	8	amod	_
7	blood	blood	NN	_	8	nn	_
8	cancer	cancer	NN	_	2	attr	2:A2=PRD
9	and	and	CC	_	2	cc	_
10	remains	remain	VBZ	pb=remain.01	2	conj	_
11	incurable	incurable	JJ	_	10	acomp	10:A3=PRD
12	,	,	,	_	10	punct	_
13	with	with	IN	_	10	prep	10:AM-ADV
14	a	a	DT	_	19	det	_
15	5	0	CD	_	17	hmod	_
16	-	-	HYPH	_	17	hyph	_
17	year	year	NN	_	19	nn	_
18	survival	survival	NN	_	19	nn	_
19	rate	rate	NN	_	13	pobj	_
20	of	of	IN	_	19	prep	_
21	44.9	0	CD	_	22	num	_
22	%	%	NN	_	20	pobj	_
23	.	.	.	_	2	punct	_

1	In	in	IN	_	6	prep	6:AM-TMP
2	2014	0	CD	_	1	pobj	_
3	,	,	,	_	6	punct	_
4	it	it	PRP	_	6	nsubjpass	_
5	is	be	VBZ	_	6	auxpass	_
6	estimated	estimate	VBN	pb=estimate.01	0	root	_
7	that	that	IN	_	14	complm	_
8	approximately	approximately	RB	_	9	advmod	_
9	24,050	0	CD	_	11	num	_
10	new	new	JJ	_	11	amod	_
11	cases	case	NNS	_	14	nsubjpass	14:A1=PPT
12	will	will	MD	_	14	aux	14:AM-MOD
13	be	be	VB	_	14	auxpass	_
14	diagnosed	diagnose	VBN	pb=diagnose.01	6	ccomp	6:A1=PPT
15	in	in	IN	_	14	prep	14:AM-LOC
16	the	the	DT	_	17	det	_
17	U.S.	u.s.	NNP	_	15	pobj	_
18	and	and	CC	_	14	cc	_
19	more	more	JJR	_	21	amod	_
20	than	than	IN	_	21	quantmod	_
21	11,000	0	CD	_	22	num	_
22	Americans	american	NNPS	_	24	nsubj	24:A1=PPT
23	will	will	MD	_	24	aux	24:AM-MOD
24	die	die	VB	pb=die.01	14	conj	_
25	from	from	IN	_	24	prep	24:AM-CAU
26	the	the	DT	_	27	det	_
27	disease	disease	NN	_	25	pobj	_
28	.	.	.	_	24	punct	_

1	Globally	globally	NNP	p2=RB	8	npadvmod	8:AM-DIS
2	,	,	,	_	8	punct	_
3	an	an	DT	_	6	det	_
4	estimated	estimate	VBN	p2=JJ|pb=estimate.01	6	amod	_
5	750,000	0	CD	_	6	num	_
6	people	people	NNS	_	8	nsubj	8:A0=PAG;4:A1=PPT
7	are	be	VBP	_	8	aux	_
8	living	live	VBG	pb=live.01	0	root	_
9	with	with	IN	_	8	prep	8:AM-MNR
10	myeloma	myeloma	NN	p2=NNS	9	pobj	_
11	.	.	.	_	8	punct	_

1	AbbVie	abbvie	NNP	_	2	nsubj	2:A1=PPT
2	is	be	VBZ	pb=be.01	0	root	_
3	a	a	DT	_	8	det	_
4	global	global	JJ	_	8	amod	_
5	,	,	,	_	8	punct	_
6	research-based	research-based	JJ	p2=VBD	8	amod	_
7	biopharmaceutical	biopharmaceutical	JJ	p2=NN	8	amod	_
8	company	company	NN	_	2	attr	9:A1=PPT;2:A2=PRD
9	formed	form	VBN	p2=VBD|pb=form.01	8	partmod	_
10	in	in	IN	_	9	prep	9:AM-TMP
11	2013	0	CD	_	10	pobj	_
12	following	follow	VBG	p2=JJ	9	prep	9:AM-TMP
13	separation	separation	NN	_	12	pobj	_
14	from	from	IN	_	13	prep	_
15	Abbott	abbott	NNP	_	16	nn	_
16	Laboratories	laboratories	NNP	p2=NNPS	14	pobj	_
17	.	.	.	_	2	punct	_

1	The	the	DT	_	2	det	_
2	company	company	NN	_	4	poss	_
3	's	's	POS	_	2	possessive	_
4	mission	mission	NN	_	5	nsubj	5:A1=PPT
5	is	be	VBZ	pb=be.01	0	root	_
6	to	to	TO	_	7	aux	_
7	use	use	VB	pb=use.01	5	xcomp	5:A2=PRD
8	its	its	PRP$	_	9	poss	_
9	expertise	expertise	NN	_	7	dobj	7:A1=PPT
10	,	,	,	_	9	punct	_
11	dedicated	dedicated	JJ	p2=VBD	12	amod	_
12	people	people	NNS	_	9	conj	_
13	and	and	CC	_	12	cc	_
14	unique	unique	JJ	_	15	amod	_
15	approach	approach	NN	_	12	conj	_
16	to	to	IN	p2=TO	15	prep	_
17	innovation	innovation	NN	_	16	pobj	_
18	to	to	TO	_	19	aux	_
19	develop	develop	VB	pb=develop.02	7	xcomp	7:A2=PRP
20	and	and	CC	_	19	cc	_
21	market	market	VB	pb=market.01	19	conj	_
22	advanced	advanced	JJ	_	23	amod	_
23	therapies	therapy	NNS	_	21	dobj	25:A0=PAG;21:A1=PPT
24	that	that	WDT	_	25	nsubj	25:R-A0
25	address	address	VBP	pb=address.02	23	rcmod	_
26	some	some	DT	_	25	dobj	25:A1=PPT
27	of	of	IN	_	26	prep	_
28	the	the	DT	_	29	det	_
29	world	world	NN	_	35	poss	_
30	's	's	POS	_	29	possessive	_
31	most	most	RBS	_	32	advmod	_
32	complex	complex	JJ	_	35	amod	_
33	and	and	CC	_	32	cc	_
34	serious	serious	JJ	_	32	conj	_
35	diseases	disease	NNS	_	27	pobj	_
36	.	.	.	_	5	punct	_

1	AbbVie	abbvie	NNP	_	2	nsubj	2:A0=PAG;8:A0=PAG
2	employs	employ	VBZ	pb=employ.01	0	root	_
3	approximately	approximately	RB	_	4	advmod	_
4	25,000	0	CD	_	5	num	_
5	people	people	NNS	_	2	dobj	2:A1=PPT
6	worldwide	worldwide	RB	_	2	advmod	2:AM-MNR
7	and	and	CC	_	2	cc	_
8	markets	market	VBZ	p2=NNS|pb=market.01	2	conj	_
9	medicines	medicine	NNS	_	8	dobj	8:A1=PPT
10	in	in	IN	_	8	prep	8:AM-LOC
11	more	more	JJR	p2=RBR	13	amod	_
12	than	than	IN	_	13	quantmod	_
13	170	0	CD	_	14	num	_
14	countries	country	NNS	_	10	pobj	_
15	.	.	.	_	2	punct	_

1	For	for	IN	p2=CC	16	prep	16:AM-PRP
2	further	far	JJ	p2=JJR	3	amod	_
3	information	information	NN	_	1	pobj	_
4	on	on	IN	_	3	prep	_
5	the	the	DT	_	6	det	_
6	company	company	NN	_	4	pobj	_
7	and	and	CC	_	6	cc	_
8	its	its	PRP$	_	9	poss	_
9	people	people	NNS	_	6	conj	_
10	,	,	,	_	9	punct	_
11	portfolio	portfolio	NN	_	9	conj	_
12	and	and	CC	_	11	cc	_
13	commitments	commitment	NNS	_	11	conj	_
14	,	,	,	_	16	punct	_
15	please	please	UH	p2=VB	16	intj	16:AM-DIS
16	visit	visit	VB	pb=visit.01	0	root	_
17	www.abbvie.com	#url#	ADD	_	16	dobj	16:A1=COM
18	.	.	.	_	16	punct	_

1	Follow	follow	VB	p2=VBP|pb=follow.01	0	root	_
2	@	@	IN	p2=,	1	prep	1:AM-MNR
3	abbvie	abbvie	NN	p2=NNP	8	nn	_
4	on	on	IN	_	3	prep	_
5	Twitter	twitter	NNP	p2=NN	4	pobj	_
6	or	or	CC	_	3	cc	_
7	view	view	NN	p2=VB	3	conj	_
8	careers	career	NNS	_	2	pobj	_
9	on	on	IN	_	8	prep	_
10	our	our	PRP$	_	11	poss	_
11	Facebook	facebook	NNP	p2=NN	9	pobj	_
12	or	or	CC	_	11	cc	_
13	LinkedIn	linkedin	NNP	_	14	nn	_
14	page	page	NN	_	11	conj	_
15	.	.	.	_	1	punct	_

1	This	this	DT	_	3	det	_
2	press	press	NN	_	3	nn	_
3	release	release	NN	_	4	nsubj	4:A0
4	contains	contain	VBZ	pb=contain.01	0	root	_
5	"	"	``	_	4	punct	_
6	forward	forward	RB	_	8	hmod	_
7	-	-	HYPH	_	8	hyph	_
8	looking	look	VBG	_	9	amod	_
9	statements	statement	NNS	_	4	dobj	4:A1
10	"	"	''	p2=``	4	punct	_
11	as	as	IN	_	15	mark	_
12	that	that	DT	_	13	det	_
13	term	term	NN	_	15	nsubjpass	15:A1=PPT
14	is	be	VBZ	_	15	auxpass	_
15	defined	define	VBN	pb=define.01	4	advcl	_
16	in	in	IN	_	15	prep	15:AM-LOC
17	the	the	DT	_	22	det	_
18	Private	private	NNP	p2=JJ	21	nn	_
19	Securities	security	NNPS	p2=NNP	21	nn	_
20	Litigation	litigation	NNP	_	21	nn	_
21	Reform	reform	NNP	_	22	nn	_
22	Act	act	NNP	_	16	pobj	_
23	of	of	IN	_	22	prep	_
24	1995	0	CD	_	23	pobj	_
25	regarding	regard	VBG	_	15	prep	_
26	the	the	DT	_	27	det	_
27	research	research	NN	_	25	pobj	_
28	,	,	,	_	27	punct	_
29	development	development	NN	_	27	conj	_
30	and	and	CC	_	29	cc	_
31	commercialization	commercialization	NN	_	29	conj	_
32	of	of	IN	_	27	prep	_
33	pharmaceutical	pharmaceutical	JJ	p2=NN	34	amod	_
34	products	product	NNS	_	32	pobj	_
35	.	.	.	_	4	punct	_

1	Such	such	JJ	p2=PDT	5	amod	_
2	forward	forward	RB	_	4	hmod	_
3	-	-	HYPH	_	4	hyph	_
4	looking	look	VBG	_	5	amod	_
5	statements	statement	NNS	_	7	nsubjpass	7:A1=PPT;12:A2=PPT
6	are	be	VBP	_	7	auxpass	_
7	based	base	VBN	pb=base.02	0	root	_
8	on	on	IN	_	7	prep	7:A2=DIR
9	current	current	JJ	_	10	amod	_
10	expectations	expectation	NNS	_	8	pobj	_
11	and	and	CC	_	7	cc	_
12	involve	involve	VBP	p2=VB|pb=involve.01	7	conj	_
13	inherent	inherent	JJ	_	14	amod	_
14	risks	risk	NNS	_	12	dobj	12:A1=PPT
15	and	and	CC	_	14	cc	_
16	uncertainties	uncertainty	NNS	_	14	conj	_
17	,	,	,	_	14	punct	_
18	including	include	VBG	_	14	prep	_
19	factors	factor	NNS	_	18	pobj	24:A0=PAG;33:A0=CAU;26:A0;22:A1=PPT
20	that	that	WDT	_	22	nsubj	22:R-A0;24:R-A0;26:R-A0;33:R-A0
21	could	could	MD	_	22	aux	22:AM-MOD;24:AM-MOD;26:AM-MOD
22	delay	delay	VB	pb=delay.01	19	rcmod	_
23	,	,	,	_	22	punct	_
24	divert	divert	VB	pb=divert.01	22	conj	_
25	or	or	CC	_	24	cc	_
26	change	change	VB	pb=change.01	24	conj	_
27	any	any	DT	_	26	dobj	26:A1=PPT
28	of	of	IN	_	27	prep	_
29	them	them	PRP	_	28	pobj	_
30	,	,	,	_	22	punct	_
31	and	and	CC	_	22	cc	_
32	could	could	MD	_	33	aux	33:AM-MOD
33	cause	cause	VB	pb=cause.01	22	conj	_
34	actual	actual	JJ	_	35	amod	_
35	outcomes	outcome	NNS	_	39	nsubj	39:A1=PPT
36	and	and	CC	_	35	cc	_
37	results	result	NNS	p2=VBZ	35	conj	_
38	to	to	TO	_	39	aux	_
39	differ	differ	VB	pb=differ.02	33	ccomp	33:A1=PPT
40	materially	materially	RB	_	39	advmod	39:AM-MNR
41	from	from	IN	_	39	prep	39:C-A1
42	current	current	JJ	_	43	amod	_
43	expectations	expectation	NNS	_	41	pobj	_
44	.	.	.	_	7	punct	_

1	No	no	DT	p2=UH	5	det	_
2	forward	forward	RB	_	4	hmod	_
3	-	-	HYPH	_	4	hyph	_
4	looking	look	VBG	_	5	amod	_
5	statement	statement	NN	_	8	nsubjpass	8:A1=PPT
6	can	can	MD	_	8	aux	8:AM-MOD
7	be	be	VB	_	8	auxpass	_
8	guaranteed	guarantee	VBN	pb=guarantee.01	0	root	_
9	.	.	.	_	8	punct	_

1	Among	among	IN	_	7	prep	7:AM-LOC
2	other	other	JJ	_	3	amod	_
3	risks	risk	NNS	_	1	pobj	_
4	,	,	,	_	7	punct	_
5	there	there	EX	_	7	expl	_
6	can	can	MD	_	7	aux	7:AM-MOD
7	be	be	VB	pb=be.02	0	root	_
8	no	no	DT	_	9	det	_
9	guarantee	guarantee	NN	_	7	attr	7:A1=PPT
10	that	that	IN	_	18	complm	_
11	the	the	DT	_	12	det	_
12	compounds	compound	NNS	_	18	nsubj	13:A1=PPT;18:A1=PPT
13	mentioned	mention	VBN	p2=VBD|pb=mention.01	12	partmod	_
14	in	in	IN	_	13	prep	13:AM-LOC
15	this	this	DT	_	16	det	_
16	release	release	NN	_	14	pobj	_
17	will	will	MD	_	18	aux	18:AM-MOD
18	move	move	VB	pb=move.01	9	ccomp	_
19	into	into	IN	_	18	prep	18:A2=GOL
20	full	full	JJ	_	22	amod	_
21	product	product	NN	_	22	nn	_
22	development	development	NN	_	19	pobj	_
23	,	,	,	_	32	punct	_
24	that	that	IN	_	32	complm	_
25	the	the	DT	_	27	det	_
26	clinical	clinical	JJ	_	27	amod	_
27	trials	trial	NNS	_	32	nsubj	32:A0
28	of	of	IN	_	27	prep	_
29	these	these	DT	_	30	det	_
30	compounds	compound	NNS	_	28	pobj	_
31	will	will	MD	_	32	aux	32:AM-MOD
32	support	support	VB	pb=support.01	18	advcl	_
33	regulatory	regulatory	JJ	_	34	amod	_
34	filings	filing	NNS	_	32	dobj	32:A1
35	,	,	,	_	32	punct	_
36	or	or	CC	_	32	cc	_
37	that	that	IN	_	41	mark	_
38	the	the	DT	_	39	det	_
39	compounds	compound	NNS	_	41	nsubj	41:A0=PAG
40	will	will	MD	_	41	aux	41:AM-MOD
41	receive	receive	VB	pb=receive.01	32	conj	_
42	regulatory	regulatory	JJ	_	43	amod	_
43	approvals	approval	NNS	_	41	dobj	41:A1=PPT
44	or	or	CC	_	41	cc	_
45	,	,	,	_	43	punct	_
46	if	if	IN	_	47	mark	_
47	approved	approve	VBN	pb=approve.01	52	advcl	_
48	,	,	,	_	47	punct	_
49	that	that	IN	p2=DT	52	complm	_
50	they	they	PRP	_	52	nsubj	52:A1=PPT
51	will	will	MD	_	52	aux	52:AM-MOD
52	become	become	VB	pb=become.01	41	conj	_
53	commercially	commercially	RB	_	54	advmod	_
54	successful	successful	JJ	_	55	amod	_
55	products	product	NNS	_	52	attr	52:A2=PRD
56	.	.	.	_	52	punct	_

1	Forward	forward	NNP	p2=JJ	3	hmod	_
2	-	-	HYPH	_	3	hyph	_
3	looking	look	VBG	_	4	amod	_
4	statements	statement	NNS	_	11	nsubjpass	11:A1=PPT
5	in	in	IN	_	4	prep	_
6	this	this	DT	_	8	det	_
7	press	press	NN	_	8	nn	_
8	release	release	NN	_	5	pobj	_
9	should	should	MD	_	11	aux	11:AM-MOD
10	be	be	VB	_	11	auxpass	_
11	evaluated	evaluate	VBN	pb=evaluate.01	0	root	_
12	together	together	RB	_	11	advmod	11:AM-MNR
13	with	with	IN	_	11	prep	11:AM-MNR
14	the	the	DT	_	16	det	_
15	many	many	JJ	_	16	amod	_
16	uncertainties	uncertainty	NNS	_	13	pobj	18:A0=PAG
17	that	that	WDT	_	18	nsubj	18:R-A0
18	affect	affect	VBP	pb=affect.01	16	rcmod	_
19	Bristol	bristol	NNP	_	21	hmod	_
20	-	-	HYPH	_	21	hyph	_
21	Myers	myers	NNP	_	22	nn	_
22	Squibb	squibb	NNP	_	24	poss	_
23	's	's	POS	_	22	possessive	_
24	business	business	NN	_	18	dobj	18:A1=PPT
25	,	,	,	_	24	punct	_
26	particularly	particularly	RB	_	27	advmod	_
27	those	those	DT	_	24	appos	28:A1=PPT
28	identified	identify	VBN	pb=identify.01	27	partmod	_
29	in	in	IN	_	28	prep	28:AM-LOC
30	the	the	DT	_	33	det	_
31	cautionary	cautionary	JJ	_	32	amod	_
32	factors	factor	NNS	_	33	nn	_
33	discussion	discussion	NN	_	29	pobj	_
34	in	in	IN	_	33	prep	_
35	Bristol	bristol	NNP	_	37	hmod	_
36	-	-	HYPH	_	37	hyph	_
37	Myers	myers	NNP	_	38	nn	_
38	Squibb	squibb	NNP	_	41	poss	_
39	's	's	POS	_	38	possessive	_
40	Annual	annual	NNP	_	41	nn	_
41	Report	report	NNP	_	34	pobj	_
42	on	on	IN	_	33	prep	_
43	Form	form	NNP	p2=NN	42	pobj	_
44	10	0	CD	p2=NNP	46	hmod	_
45	-	-	HYPH	p2=:	46	hyph	_
46	K	k	NNP	p2=NN	43	appos	_
47	for	for	IN	_	28	prep	_
48	the	the	DT	_	49	det	_
49	year	year	NN	_	47	pobj	50:A1
50	ended	ended	VBN	p2=VBD|pb=end.01	49	partmod	_
51	December	december	NNP	_	50	npadvmod	50:AM-TMP
52	31	0	CD	_	51	num	_
53	,	,	,	_	49	punct	_
54	2013	0	CD	_	49	appos	_
55	in	in	IN	_	54	prep	_
56	our	our	PRP$	_	58	poss	_
57	Quarterly	quarterly	NNP	_	58	nn	_
58	Reports	report	NNS	p2=NNPS	55	pobj	_
59	on	on	IN	_	58	prep	_
60	Form	form	NN	p2=NNP	59	pobj	_
61	10	0	CD	_	63	hmod	_
62	-	-	HYPH	p2=SYM	63	hyph	_
63	Q	q	NNP	p2=NN	60	appos	_
64	and	and	CC	_	63	cc	_
65	our	our	PRP$	_	67	poss	_
66	Current	current	JJ	_	67	amod	_
67	Reports	report	NNS	_	63	conj	_
68	on	on	IN	_	67	prep	_
69	Form	form	NN	p2=NNP	68	pobj	_
70	8	0	CD	_	69	num	_
71	-	-	HYPH	p2=SYM	72	hyph	_
72	K	k	NN	p2=NNP	69	appos	_
73	.	.	.	_	11	punct	_

1	Bristol	bristol	NNP	_	3	hmod	_
2	-	-	HYPH	_	3	hyph	_
3	Myers	myers	NNP	_	4	nn	_
4	Squibb	squibb	NNP	_	5	nsubj	5:A0=PAG
5	undertakes	undertake	VBZ	pb=undertake.01	0	root	_
6	no	no	DT	_	7	det	_
7	obligation	obligation	NN	_	5	dobj	5:A1=PPT
8	to	to	TO	_	10	aux	_
9	publicly	publicly	RB	_	10	advmod	10:AM-MNR
10	update	update	VB	pb=update.01	7	infmod	_
11	any	any	DT	_	15	det	_
12	forward	forward	RB	_	14	hmod	_
13	-	-	HYPH	_	14	hyph	_
14	looking	look	VBG	_	15	amod	_
15	statement	statement	NN	_	10	dobj	10:A1=PPT
16	,	,	,	_	5	punct	_
17	whether	whether	IN	_	18	preconj	_
18	as	as	IN	_	10	prep	10:AM-ADV
19	a	a	DT	_	20	det	_
20	result	result	NN	_	18	pobj	_
21	of	of	IN	_	20	prep	_
22	new	new	JJ	_	23	amod	_
23	information	information	NN	_	21	pobj	_
24	,	,	,	_	23	punct	_
25	future	future	JJ	p2=NN	26	amod	_
26	events	event	NNS	_	23	conj	_
27	or	or	CC	_	26	cc	_
28	otherwise	otherwise	RB	_	26	conj	_
29	.	.	.	_	5	punct	_

1	Some	some	DT	_	2	det	_
2	statements	statement	NNS	_	8	nsubj	8:A1=PPT
3	in	in	IN	_	2	prep	_
4	this	this	DT	_	6	det	_
5	news	news	NN	_	6	nn	_
6	release	release	NN	_	3	pobj	_
7	may	may	MD	_	8	aux	8:AM-MOD
8	be	be	VB	pb=be.01	0	root	_
9	forward	forward	RB	_	11	hmod	_
10	-	-	HYPH	_	11	hyph	_
11	looking	look	VBG	_	12	amod	_
12	statements	statement	NNS	_	8	attr	8:A2=PRD
13	for	for	IN	_	12	prep	_
14	purposes	purpose	NNS	_	13	pobj	_
15	of	of	IN	_	14	prep	_
16	the	the	DT	_	21	det	_
17	Private	private	NNP	p2=JJ	20	nn	_
18	Securities	security	NNPS	p2=NNP	20	nn	_
19	Litigation	litigation	NNP	_	20	nn	_
20	Reform	reform	NNP	_	21	nn	_
21	Act	act	NNP	_	15	pobj	_
22	of	of	IN	_	21	prep	_
23	1995	0	CD	_	22	pobj	_
24	.	.	.	_	8	punct	_

1	The	the	DT	_	2	det	_
2	words	word	NNS	_	4	nsubj	4:A0=PAG
3	"	"	``	p2=''	2	punct	_
4	believe	believe	VBP	p2=VB|pb=believe.01	0	root	_
5	,	,	,	_	4	punct	_
6	"	"	''	_	8	punct	_
7	"	"	``	_	8	punct	_
8	expect	expect	VB	p2=VBP|pb=expect.01	4	xcomp	4:A1=PPT
9	,	,	,	_	8	punct	_
10	"	"	''	_	12	punct	_
11	"	"	``	_	12	punct	_
12	anticipate	anticipate	VBP	p2=VB|pb=anticipate.01	8	conj	_
13	,	,	,	_	12	punct	_
14	"	"	''	_	16	punct	_
15	"	"	``	_	16	punct	_
16	project	project	NN	_	12	conj	_
17	"	"	''	_	16	punct	_
18	and	and	CC	_	16	cc	_
19	similar	similar	JJ	_	20	amod	_
20	expressions	expression	NNS	_	16	conj	_
21	,	,	,	_	20	punct	_
22	among	among	IN	_	16	prep	_
23	others	other	NNS	_	22	pobj	_
24	,	,	,	_	26	punct	_
25	generally	generally	RB	_	26	advmod	26:AM-ADV
26	identify	identify	VBP	p2=VB|pb=identify.01	12	conj	_
27	forward	forward	RB	_	29	hmod	_
28	-	-	HYPH	_	29	hyph	_
29	looking	look	VBG	_	30	amod	_
30	statements	statement	NNS	_	26	dobj	26:A1=PPT
31	.	.	.	_	4	punct	_

1	AbbVie	abbvie	NNP	_	2	nsubj	2:A0=PAG
2	cautions	caution	VBZ	pb=caution.01	0	root	_
3	that	that	IN	_	9	complm	_
4	these	these	DT	_	8	det	_
5	forward	forward	RB	_	7	hmod	_
6	-	-	HYPH	_	7	hyph	_
7	looking	look	VBG	_	8	amod	_
8	statements	statement	NNS	_	9	nsubj	9:A1=PPT
9	are	be	VBP	pb=be.01	2	ccomp	2:A1=PPT
10	subject	subject	JJ	_	9	acomp	9:A2=PRD
11	to	to	IN	_	10	prep	_
12	risks	risk	NNS	_	11	pobj	17:A0=CAU
13	and	and	CC	_	12	cc	_
14	uncertainties	uncertainty	NNS	_	12	conj	_
15	that	that	WDT	_	17	nsubj	17:R-A0
16	may	may	MD	_	17	aux	17:AM-MOD
17	cause	cause	VB	pb=cause.01	12	rcmod	_
18	actual	actual	JJ	_	19	amod	_
19	results	result	NNS	_	21	nsubj	21:A1=PPT
20	to	to	TO	_	21	aux	_
21	differ	differ	VB	pb=differ.02	17	ccomp	17:A1=PPT
22	materially	materially	RB	_	21	advmod	21:AM-MNR
23	from	from	IN	_	21	prep	21:C-A1
24	those	those	DT	_	23	pobj	25:A1=PPT
25	indicated	indicate	VBN	p2=VBD|pb=indicate.01	24	partmod	_
26	in	in	IN	_	25	prep	25:AM-LOC
27	the	the	DT	_	31	det	_
28	forward	forward	RB	_	30	hmod	_
29	-	-	HYPH	_	30	hyph	_
30	looking	look	VBG	_	31	amod	_
31	statements	statement	NNS	_	26	pobj	_
32	.	.	.	_	2	punct	_

1	Such	such	JJ	_	2	amod	_
2	risks	risk	NNS	_	5	nsubj	5:A2=GOL
3	and	and	CC	_	2	cc	_
4	uncertainties	uncertainty	NNS	_	2	conj	_
5	include	include	VBP	pb=include.01	0	root	_
6	,	,	,	_	5	punct	_
7	but	but	CC	_	5	cc	_
8	are	be	VBP	_	10	auxpass	_
9	not	not	RB	_	10	neg	10:AM-NEG
10	limited	limit	VBN	p2=JJ|pb=limit.01	5	conj	_
11	to	to	IN	_	10	prep	10:A2=GOL
12	,	,	,	_	5	punct	_
13	challenges	challenge	NNS	p2=VBZ	11	pobj	_
14	to	to	IN	_	13	prep	_
15	intellectual	intellectual	JJ	_	16	amod	_
16	property	property	NN	_	14	pobj	_
17	,	,	,	_	16	punct	_
18	competition	competition	NN	_	16	conj	_
19	from	from	IN	_	18	prep	_
20	other	other	JJ	_	21	amod	_
21	products	product	NNS	_	19	pobj	_
22	,	,	,	_	21	punct	_
23	difficulties	difficulty	NNS	_	21	conj	_
24	inherent	inherent	JJ	_	23	amod	_
25	in	in	IN	_	24	prep	_
26	the	the	DT	_	30	det	_
27	research	research	NN	_	30	nn	_
28	and	and	CC	_	27	cc	_
29	development	development	NN	_	27	conj	_
30	process	process	NN	_	25	pobj	_
31	,	,	,	_	30	punct	_
32	adverse	adverse	JJ	_	33	amod	_
33	litigation	litigation	NN	_	27	conj	_
34	or	or	CC	_	33	cc	_
35	government	government	NN	_	36	nn	_
36	action	action	NN	_	33	conj	_
37	,	,	,	_	33	punct	_
38	and	and	CC	_	33	cc	_
39	changes	change	NNS	p2=VBZ	33	conj	_
40	to	to	IN	_	39	prep	_
41	laws	law	NNS	_	40	pobj	_
42	and	and	CC	_	41	cc	_
43	regulations	regulation	NNS	_	41	conj	_
44	applicable	applicable	JJ	_	41	amod	_
45	to	to	IN	_	44	prep	_
46	our	our	PRP$	_	47	poss	_
47	industry	industry	NN	_	45	pobj	_
48	.	.	.	_	5	punct	_

1	Additional	additional	JJ	_	2	amod	_
2	information	information	NN	_	22	nsubjpass	22:A1=PPT
3	about	about	IN	_	2	prep	_
4	the	the	DT	_	14	det	_
5	economic	economic	JJ	_	14	amod	_
6	,	,	,	_	5	punct	_
7	competitive	competitive	JJ	_	5	conj	_
8	,	,	,	_	7	punct	_
9	governmental	governmental	JJ	_	7	conj	_
10	,	,	,	_	9	punct	_
11	technological	technological	JJ	_	9	conj	_
12	and	and	CC	_	11	cc	_
13	other	other	JJ	_	11	conj	_
14	factors	factor	NNS	_	3	pobj	17:A0=PAG
15	that	that	WDT	_	17	nsubj	17:R-A0
16	may	may	MD	_	17	aux	17:AM-MOD
17	affect	affect	VB	pb=affect.01	14	rcmod	_
18	AbbVie	abbvie	NNP	_	20	poss	_
19	's	's	POS	_	18	possessive	_
20	operations	operation	NNS	_	17	dobj	17:A1=PPT
21	is	be	VBZ	_	22	auxpass	_
22	set	set	VBN	pb=set.01	0	root	_
23	forth	forth	RB	p2=RP	22	advmod	22:A2=LOC
24	in	in	IN	_	22	prep	22:AM-LOC
25	Item	item	NNP	_	26	nn	_
26	1A	1a	NNP	_	24	pobj	_
27	,	,	,	_	22	punct	_
28	"	"	''	p2=``	30	punct	_
29	Risk	risk	NN	p2=NNP	30	nn	_
30	Factors	factors	NNP	p2=NNS	49	npadvmod	_
31	,	,	,	_	49	punct	_
32	"	"	''	p2=``	22	punct	_
33	in	in	IN	_	49	prep	_
34	our	our	PRP$	_	37	poss	_
35	2012	0	CD	_	37	num	_
36	Annual	annual	NNP	_	37	nn	_
37	Report	report	NNP	_	33	pobj	_
38	on	on	IN	_	37	prep	_
39	Form	form	NNP	p2=NN	38	pobj	_
40	10	0	CD	p2=NNP	42	hmod	_
41	-	-	HYPH	p2=:	42	hyph	_
42	K	k	NNP	p2=NN	44	nn	_
43	/	/	,	p2=NNP	42	punct	_
44	A	a	NNP	p2=DT	14	appos	49:A1
45	,	,	,	_	44	punct	_
46	which	which	WDT	_	49	nsubjpass	49:R-A1
47	has	have	VBZ	_	49	aux	_
48	been	be	VBN	_	49	auxpass	_
49	filed	file	VBN	pb=file.01	44	rcmod	_
50	with	with	IN	_	49	prep	49:A2=GOL
51	the	the	DT	_	55	det	_
52	Securities	security	NNPS	p2=NNP	55	nn	_
53	and	and	CC	_	52	cc	_
54	Exchange	exchange	NNP	_	52	conj	_
55	Commission	commission	NNP	_	50	pobj	_
56	.	.	.	_	22	punct	_

1	AbbVie	abbvie	NNP	_	2	nsubj	2:A0=PAG
2	undertakes	undertake	VBZ	pb=undertake.01	0	root	_
3	no	no	DT	_	4	det	_
4	obligation	obligation	NN	_	2	dobj	2:A1=PPT
5	to	to	TO	_	6	aux	_
6	release	release	VB	pb=release.01	4	infmod	_
7	publicly	publicly	RB	_	6	advmod	6:AM-MNR
8	any	any	DT	_	9	det	_
9	revisions	revision	NNS	_	6	dobj	6:A1=PPT
10	to	to	IN	p2=TO	9	prep	_
11	forward	forward	RB	_	13	hmod	_
12	-	-	HYPH	_	13	hyph	_
13	looking	look	VBG	_	14	amod	_
14	statements	statement	NNS	_	10	pobj	_
15	as	as	IN	_	14	prep	_
16	a	a	DT	_	17	det	_
17	result	result	NN	_	15	pobj	_
18	of	of	IN	_	17	prep	_
19	subsequent	subsequent	JJ	_	20	amod	_
20	events	event	NNS	_	18	pobj	_
21	or	or	CC	_	20	cc	_
22	developments	development	NNS	_	20	conj	_
23	,	,	,	_	17	punct	_
24	except	except	IN	_	17	prep	_
25	as	as	IN	_	26	mark	_
26	required	require	VBN	pb=require.01	24	pcomp	_
27	by	by	IN	_	26	agent	26:A0=PAG
28	law	law	NN	_	27	pobj	_
29	.	.	.	_	2	punct	_

